| MA, JIONG |
NCT04280185: HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC) |
|
|
| Recruiting | N/A | 202 | RoW | Hyperthermic Intraperitoneal Chemotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang University | Ovarian Cancer, Hyperthermic Intraperitoneal Chemotherapy | 05/22 | 05/24 | | |
| Chen, Xuejun |
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer |
|
|
| Recruiting | 3 | 35 | RoW | Mirvetuximab Soravtansine, IMGN853, MIRV | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 04/23 | 12/23 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
NCT04280185: HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC) |
|
|
| Recruiting | N/A | 202 | RoW | Hyperthermic Intraperitoneal Chemotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang University | Ovarian Cancer, Hyperthermic Intraperitoneal Chemotherapy | 05/22 | 05/24 | | |
